Syntaxin Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 28

Employees

  • Latest Deal Type
  • 2ndary - Private

Syntaxin General Information

Description

Provider of biologics platform generating a pipeline of Targeted Secretion Inhibitors (TSIs) to treat diseases where secretion is the major driver, including pain, endocrine conditions and cancer. The company genetically engineers bacterial toxins to develop novel drugs that inhibit abnormal cell secretion, a key component of many diseases. The company is focused on the treatment of neurological, inflammatory and endocrine diseases.

Contact Information

Website
www.syntaxin.com
Formerly Known As
Syntaxin Ltd.
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Units 4-10 The Quadrant
  • Barton Lane
  • Abingdon OX14 3YS
  • England, United Kingdom
Primary Industry
Biotechnology
Acquirer
Ipsen
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Units 4-10 The Quadrant
  • Barton Lane
  • Abingdon OX14 3YS
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Syntaxin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 18-Dec-2024 Completed Clinical Trials - Phase 2
5. Merger/Acquisition 17-Jul-2013 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 11-Nov-2010 Completed Generating Revenue
3. Early Stage VC (Series B) 01-Oct-2007 Completed Generating Revenue
2. Grant 06-Jul-2006 $2.21M $10.6M Completed Product Development
1. Early Stage VC (Series A) 14-Nov-2005 $10.6M $10.6M Completed Product Development
To view Syntaxin’s complete valuation and funding history, request access »

Syntaxin Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of biologics platform generating a pipeline of Targeted Secretion Inhibitors (TSIs) to treat diseases where sec
Biotechnology
Abingdon, United Kingdom
28 As of 2015

Somerville, MA
 

Lyon, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Syntaxin Competitors (47)

One of Syntaxin’s 47 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Phaxiam Formerly VC-backed Lyon, France
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
Arrowhead Pharmaceuticals Corporation Pasadena, CA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
You’re viewing 5 of 47 competitors. Get the full list »

Syntaxin Patents

  • 583

    Total Documents Applications and Grants

  • Total Patents Families

  • 281

    Granted

  • 22

    Pending

  • Expiring in next 12 mo

Syntaxin Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202011055-D0 Treatment of post-operative pain Inactive 17-Jul-2020
JP-2021104047-A Cationic neurotoxin Active 09-Aug-2019
JP-6867452-B2 Cationic neurotoxin Active 09-Aug-2019
JP-7328275-B2 Cationic neurotoxin Active 09-Aug-2019
JP-2019206582-A Cationic neurotoxins Active 09-Aug-2019
To view Syntaxin’s complete patent history, request access »

Syntaxin Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Syntaxin Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abingworth Venture Capital Minority
EQT Life Sciences Venture Capital Minority
Health Protection Agency Corporation Minority
Johnson & Johnson JJDC Corporate Venture Capital Minority
Lundbeckfonden BioCapital Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Syntaxin FAQs

  • When was Syntaxin founded?

    Syntaxin was founded in 2005.

  • Where is Syntaxin headquartered?

    Syntaxin is headquartered in Abingdon, United Kingdom.

  • What is the size of Syntaxin?

    Syntaxin has 28 total employees.

  • What industry is Syntaxin in?

    Syntaxin’s primary industry is Biotechnology.

  • Is Syntaxin a private or public company?

    Syntaxin is a Private company.

  • What is Syntaxin’s current revenue?

    The current revenue for Syntaxin is .

  • How much funding has Syntaxin raised over time?

    Syntaxin has raised $71.3M.

  • Who are Syntaxin’s investors?

    Abingworth, EQT Life Sciences, Health Protection Agency, Johnson & Johnson JJDC, and Lundbeckfonden BioCapital are 5 of 8 investors who have invested in Syntaxin.

  • Who are Syntaxin’s competitors?

    Genetix Biotherapeutics, Phaxiam, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, and Sangamo Therapeutics are some of the 47 competitors of Syntaxin.

  • When was Syntaxin acquired?

    Syntaxin was acquired on 18-Dec-2024.

  • Who acquired Syntaxin?

    Syntaxin was acquired by Ipsen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process